Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Gao-Yang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of International Business, China Pharmaceutical University, Nanjing, Jiangsu 211198, China. Hauptthemen laut MEDLINE: Reverse Transcriptase Inhibitors, Adverse Drug Reaction Reporting Systems, HIV Integrase Inhibitors, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background and objectives Integrase strand transfer inhibitors (INSTIs) and NNRTIs are widely used in the treatment of HIV, but the real-world adverse events (AEs) profiles of these drugs remain inadequately characterized. We prioritized AEs reported with INSTIs and NNRTIs using data from the FDA Adverse Event Reporting System (FAERS).
Methods
Using FAERS data (from FDA approval to June 2024) for 10 drugs (cabotegravir, dolutegravir, raltegravir, elvitegravir, bictegravir, nevirapine, efavirenz, rilpivirine, doravirine and etravirine), we assessed AE clinical priority using a multi-criteria score. The score evaluated four criteria: clinical relevance, reporting proportion, case fatality rate and signal stability. We calculated reporting odds ratios (RORs) with 95% CIs; signals required the lower limit of 95% CIs of the ROR, ROR025 > 1 after Bonferroni correction across [N] tested AEs per drug. Events related to medication errors or HIV-related conditions were excluded. A case-by-case assessment was conducted to evaluate the confounding factors from co-medications and indications Results We found 4487/6362 (70.5%) were low priority (0–2 points) and 1849/6362 (29.1%) were moderate (3–5 points), 2, 8, 6 and 15 marginally high-priority (≥4.5 points) adverse pregnancy outcomes were identified with dolutegravir, raltegravir, nevirapine, efavirenz, respectively; 26 AEs were high clinical priorities (>5 points). After case-by-case assessment, five noteworthy AEs remained. These included efavirenz-related haemolytic anaemia, etravirine-related hepatic failure, dolutegravir-related foetal death, raltegravir-related drug reaction with eosinophilia and systemic symptoms, and raltegravir-related hepatic failure.
Conclusions
This study provides a systematic framework for evaluating post-marketing AEs of INSTIs and NNRTIs using a semi-quantitative scoring system. Our findings identified five high-priority AEs that require clinical validation and further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of International Business, China Pharmaceutical University, Nanjing, Jiangsu 211198, China.
- Sorbonne Université, INSERM, CIC-1901 Paris-Est, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France.
- Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA.
- Division of Oncology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA.
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu-shi, Gifu 501-1196, Japan.
ORCID-Profile: Yoshihiro Noguchi
Zitieren
APA
Wang, G. Y., Xia, S., Sarangdhar, M., Noguchi, Y., & Zhou, J. F. (2026). Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag074
Vancouver
Wang GY, Xia S, Sarangdhar M, Noguchi Y, Zhou JF. Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag074
BibTeX
@article{Wang2026,
author = {Wang, Gao-Yang and Xia, Shuang and Sarangdhar, Mayur and Noguchi, Yoshihiro and Zhou, Ji-Fang},
title = {Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag074}
}
EUVIMED